❗️ Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer (ACHILES) HR 1.14 (0.76-1.71) 👎 and makes me wonder re: ADRIATIC as well 🤔 #ASCO25

🔥NSABP- B51 is out! Practice changing trial supporting RT de-escalation in cN1, ypN0 breast cancer 👉longer follow up desired 👉applicability across subtypes? 👉Impact of more modern systemic therapies ? NRG Oncology ASTRO #BreastCancer nejm.org/doi/full/10.10…

👉🏻 Our new publication suggests no survival benefit from adding CHT to RT in stage II NPC 👉🏻 While RT alone was effective overall, selected patients might still benefit from tailored use of CHT⁉️ 👉🏻 CONC: More data needed ✅ Melek Tugce Yilmaz MD Sepideh Mohammadipour onkder.org/abstract.php?l…

Stereotactic Ablative Body Radiotherapy for Oligoprogressive Estrogen Receptor–Positive Breast Cancer (TROG 20.03 AVATAR): A Phase II Prospective Multicenter Trial | JCO Oncology Advances ascopubs.org/doi/10.1200/OA…

🚀 New from our clinic! "Gyroscopic Radiosurgery-Based Lattice Therapy for intracranial tumors" now published! 📝 Read our innovative article & support us by voting in the “Dedicated Cranial Radiosurgery” competition! 🔗cureus.com/articles/36963… Cureus Sepideh Mohammadipour

💥 Just published! Does Anterior Commissure Involvement Matter for Early‐Stage Glottic Cancer in the Intensity‐Modulated Radiotherapy Era? ✅ Our latest study is now available online! 👉🏻 onlinelibrary.wiley.com/doi/10.1002/he… Melek Tugce Yilmaz MD Sepideh Mohammadipour #Radiotherapy #GlotticCancer #IMRT

🆕 Just published in @GynOncJnls ! Our new study explores prognostic heterogeneity in FIGO 2023 stage IIC endometrial cancer. 🌊 One sea, different depths 🌊 👉🏻 sciencedirect.com/science/articl…

🚨 Just out in Red Journal! We analyzed our 191-patient H&N reirradiation cohort, with a specific focus on toxicity and CBOS 📊 Real-world SBRT data 🧑‍⚕️ Lessons on patient selection & risk mitigation redjournal.org/article/S0360-… IJROBP - The Red Journal Gozde Yazici Alper Kahvecioglu MD Ecem Yigit

Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a phase 3 thelancet.com/journals/lanon… Authors: Alison Tree 💙, Nicholas van As, & Prof Emma Hall The Royal Marsden Cancer Charity, Accuray, The ICR

Read a new #RedJournal article from Melek Tugce Yilmaz MD et al on 15 Years of Experience with Stereotactic Body Radiotherapy for Recurrent Head and Neck Cancers: A Detailed Analysis of Patients with Carotid Blowout Syndrome. tinyurl.com/yilmazred

No PCI and SRS for limited mets in SCLC under close follow-up — I believe this is the new standard. I’ve been using this approach for 5+ years with no regrets ascopubs.org/doi/10.1200/JC…

In high-risk prostate cancer, radiotherapy plus ADT significantly reduces the risk of distant metastasis compared to surgery-based approaches. However, post-metastasis survival does not differ between treatments. European Urology Oncology Daniel E Spratt OncoAlert Advanced Prostate Cancer Consensus Conference European Association of Urology (EAU)

📢Important preclinical work in Advances, an ASTRO Journal supporting clinical observations that proton sensitivity of normal tissues like spinal cord can be greater than expected⚠️ Rachel Jimenez, MD Ari E. Marciscano, MD Sophia Kamran, MD Steven H. Lin advancesradonc.org/article/S2452-…

No role for mediastinal LN dissection in clinical stage T1N0M0 GGO-dominant invasive lung adeno, defined by consolidation-to-tumor ratio (CTR) ≤0.5 & maximum tumor diameter (including solid and GGO components) ≤3 cm. Zero positive hilar nodes in those that were resected!

Just published in The Lancet! ‼️🗞️ ESGO-ESTRO-ESP Guidelines for the Management of Patients with Endometrial Carcinoma: 2025 Update These guidelines are an update from the prior guidelines published in 2021 and cover all relevant aspects of diagnosis, management, follow-up &

⚡️Today's FDA Accelerated Approval of ONC201 for H3 K27M-Mutant Diffuse Midline Glioma is TROUBLING! ONC201 is celebrated as a breakthrough in the treatment of one of the most devastating brain cancers, but the reality is very different 👇 Best available data show that this